Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.


Autoria(s): Delforge M.; Minuk L.; Eisenmann J.C.; Arnulf B.; Canepa L.; Fragasso A.; Leyvraz S.; Langer C.; Ezaydi Y.; Vogl D.T.; Giraldo-Castellano P.; Yoon S.S.; Zarnitsky C.; Escoffre-Barbe M.; Lemieux B.; Song K.; Bahlis N.J.; Guo S.; Monzini M.S.; Ervin-Haynes A.; Houck V.; Facon T.
Data(s)

2015

Resumo

We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of lenalidomide and low-dose dexamethasone for 18 months; or iii) fixed cycles of melphalan, prednisone, thalidomide for 18 months. Data were collected using the validated questionnaires (QLQ-MY20, QLQ-C30, and EQ-5D). The analysis focused on the EQ-5D utility value and six domains pre-selected for their perceived clinical relevance. Lenalidomide and low-dose dexamethasone, and melphalan, prednisone, thalidomide improved patients' health-related quality-of-life from baseline over the duration of the study across all pre-selected domains of the QLQ-C30 and EQ-5D. In the QLQ-MY20, lenalidomide and low-dose dexamethasone demonstrated a significantly greater reduction in the Disease Symptoms domain compared with melphalan, prednisone, thalidomide at Month 3, and significantly lower scores for QLQ-MY20 Side Effects of Treatment at all post-baseline assessments except Month 18. Linear mixed-model repeated-measures analyses confirmed the results observed in the cross-sectional analysis. Continuous lenalidomide and low-dose dexamethasone delays disease progression versus melphalan, prednisone, thalidomide and has been associated with a clinically meaningful improvement in health-related quality-of-life. These results further establish continuous lenalidomide and low-dose dexamethasone as a new standard of care for initial therapy of myeloma by demonstrating superior health-related quality-of-life during treatment, compared with melphalan, prednisone, thalidomide.

Identificador

http://serval.unil.ch/?id=serval:BIB_88BF6238C995

isbn:1592-8721 (Electronic)

pmid:25769541

doi:10.3324/haematol.2014.120121

isiid:000358577000027

Idioma(s)

en

Fonte

Haematologica, vol. 100, no. 6, pp. 826-833

Tipo

info:eu-repo/semantics/article

article